Head/Neck Cancer

Top Story

Biocept, UT Southwestern to study liquid biopsy platform in ALK-positive non-small cell lung cancer

August 18, 2017

Biocept Inc. and University of Texas Southwestern Medical Center entered a clinical study agreement to evaluate the clinical utility of Biocept’s Target Selector platform for patients with ALK-positive non-small cell lung cancer.

The liquid biopsy platform is designed to capture and analyze tumor-associated molecular markers in both circulating tumor cells and circulating tumor DNA to identify cancer mutations and alterations that can inform physicians about a patient's disease and potential therapeutic options.

In the Journals Plus

HPV behind nearly 75% of oropharyngeal cancer cases in Canada

August 16, 2017
The proportion of oropharyngeal cancers associated with HPV in several cancer centers across Canada rose from nearly half to nearly three-quarters over 12 years…
In the Journals Plus

Older patients with cancer may burden caregivers by overestimating physical abilities

August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
FDA News

FDA removes clinical hold on study of Multikine for head and neck cancer

August 14, 2017
The FDA removed the clinical hold from a phase 3 study designed to evaluate leukocyte interleukin injection for the treatment of newly diagnosed head and neck cancer…
More Headlines »
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
Meeting News

VIDEO: Role of adjuvant chemotherapy in nasopharynx cancer remains uncertain

June 19, 2017
More »
Resource Centers

CME

The Patient with Lymphadenopathy

No commercial support for this activity.

Castleman’s disease is a rare lymphoproliferative disorder that is characterized by enlargement of 1 (unicentric) or…
More »
Advertisement
Advertisement